Axon Enterprise, Inc. (NASDAQ:AXON) Receives $488.67 Consensus Target Price from Analysts

Shares of Axon Enterprise, Inc. (NASDAQ:AXON) have earned an average recommendation of “Buy” from the thirteen brokerages that are presently covering the company, Marketbeat.com reports. Thirteen equities research analysts have rated the stock with a buy recommendation. The average 1-year target price among analysts that have issued a report on the stock in the last year is $488.67.

AXON has been the topic of a number of recent research reports. JMP Securities raised their price objective on shares of Axon Enterprise from $430.00 to $500.00 and gave the company a “market outperform” rating in a research note on Thursday, October 31st. Needham & Company LLC raised their price target on shares of Axon Enterprise from $525.00 to $600.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Northland Securities boosted their price objective on Axon Enterprise from $365.00 to $550.00 and gave the stock an “outperform” rating in a report on Monday, November 11th. Robert W. Baird raised their target price on Axon Enterprise from $600.00 to $800.00 and gave the company an “outperform” rating in a report on Friday, December 6th. Finally, The Goldman Sachs Group upped their price target on Axon Enterprise from $385.00 to $441.00 and gave the stock a “buy” rating in a report on Wednesday, October 23rd.

Axon Enterprise Trading Down 5.0 %

NASDAQ AXON opened at $570.71 on Tuesday. Axon Enterprise has a 52 week low of $244.01 and a 52 week high of $698.67. The business has a 50 day moving average price of $596.20 and a 200-day moving average price of $443.16. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32. The company has a market cap of $43.52 billion, a price-to-earnings ratio of 147.47, a P/E/G ratio of 14.19 and a beta of 1.04.

Insider Buying and Selling

In related news, insider Jeffrey C. Kunins sold 21,834 shares of Axon Enterprise stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $593.88, for a total value of $12,966,775.92. Following the sale, the insider now owns 154,394 shares of the company’s stock, valued at approximately $91,691,508.72. The trade was a 12.39 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $604.07, for a total value of $271,831.50. Following the transaction, the director now directly owns 6,929 shares of the company’s stock, valued at approximately $4,185,601.03. This trade represents a 6.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 51,545 shares of company stock worth $31,159,317. Insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On Axon Enterprise

Several institutional investors have recently added to or reduced their stakes in the business. Quent Capital LLC raised its position in shares of Axon Enterprise by 1,875.0% in the third quarter. Quent Capital LLC now owns 79 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 75 shares during the period. Prestige Wealth Management Group LLC raised its holdings in Axon Enterprise by 115.8% during the 3rd quarter. Prestige Wealth Management Group LLC now owns 82 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 44 shares during the period. Brooklyn Investment Group purchased a new stake in shares of Axon Enterprise during the third quarter worth $41,000. Asset Dedication LLC bought a new position in shares of Axon Enterprise in the second quarter worth $47,000. Finally, Planning Capital Management Corp raised its stake in shares of Axon Enterprise by 83.3% during the 3rd quarter. Planning Capital Management Corp now owns 121 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 55 shares during the period. 79.08% of the stock is owned by hedge funds and other institutional investors.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.